Top

Published in:

Open Access 01-08-2020 | Human Papillomavirus | Original Article

Epstein–Barr virus (EBV) and polyomaviruses are detectable in oropharyngeal cancer and EBV may have prognostic impact

Authors: Timo Carpén, Stina Syrjänen, Lauri Jouhi, Reija Randen-Brady, Caj Haglund, Antti Mäkitie, Petri S. Mattila, Jaana Hagström

Published in: Cancer Immunology, Immunotherapy | Issue 8/2020

Abstract

Background

The etiological role of human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma (OPSCC) is confirmed. However, the role of other oncoviruses in OPSCC is unknown.

Materials and methods

A total of 158 consecutive OPSCC patients treated with curative intent were included. DNA extracted from tumor sections was used to detect Epstein–Barr virus (EBV), HPV, and the following polyomaviruses: John Cunningham virus (JCV), Simian virus 40 (SV40), and BK virus (BKV) with PCR. In addition, p16 expression was studied by immunohistochemistry, and EBV-encoded small RNA (EBER) transcripts were localized by in situ hybridization. The effect of viral status on overall survival (OS) and disease-free survival (DFS) was analyzed.

Results

A total of 94/158 samples (59.5%) were HPV-positive, 29.1% contained BKV DNA, 20.3% EBV DNA, 13.9% JCV DNA, and 0.6% SV40 DNA. EBER was expressed only in stromal lymphocytes adjacent to the tumor and correlated with HPV positivity (p = 0.026). p16 expression associated only with HPV. None of the three polyomaviruses had an impact on survival. Patients with EBER-positive but HPV-negative OPSCC had significantly poorer OS and DFS than those with HPV-positive OPSCC and slightly worse prognosis compared with the patients with EBER-negative and HPV-negative OPSCC.

Conclusion

Polyomaviruses are detectable in OPSCC but seem to have no impact on survival, whereas HPV was the strongest viral prognostic factor. EBER expression, as a sign of latent EBV infection, may have prognostic impact among patients with HPV-negative OPSCC. EBER analysis may identify a new subgroup of OPSCCs unrelated to HPV.

Ruuskanen M, Irjala H, Minn H, Vahlberg T, Randen-Brady R, Hagstrom J, Syrjanen S, Leivo I (2019) Epstein-Barr virus and human papillomaviruses as favorable prognostic factors in nasopharyngeal carcinoma: a nationwide study in Finland. Head Neck 41(2):349–357. https://doi.org/10.1002/hed.25450 CrossRefPubMed

Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35. https://doi.org/10.1056/NEJMoa0912217 CrossRefPubMedPubMedCentral

Poluschkin L, Rautava J, Turunen A, Wang Y, Hedman K, Syrjanen K, Grenman R, Syrjanen S (2018) Polyomaviruses detectable in head and neck carcinomas. Oncotarget 9(32):22642–22652. https://doi.org/10.18632/oncotarget.25202 CrossRefPubMedPubMedCentral

Turunen A, Rautava J, Grenman R, Syrjanen K, Syrjanen S (2017) Epstein-Barr virus (EBV)-encoded small RNAs (EBERs) associated with poor prognosis of head and neck carcinomas. Oncotarget 8(16):27328–27338. https://doi.org/10.18632/oncotarget.16033 CrossRefPubMed

Guidry JT, Scott RS (2017) The interaction between human papillomavirus and other viruses. Virus Res 231:139–147. https://doi.org/10.1016/j.virusres.2016.11.002 CrossRefPubMed

Dickinson A, Xu M, Silen S, Wang Y, Fu Y, Sadeghi M, Toppinen M, Carpen T, Hedman K, Makitie A, Soderlund-Venermo M (2019) Newly detected DNA viruses in juvenile nasopharyngeal angiofibroma (JNA) and oral and oropharyngeal squamous cell carcinoma (OSCC/OPSCC). Eur Arch Otorhinolaryngol 276(2):613–617. https://doi.org/10.1007/s00405-018-5250-7 CrossRefPubMed

Shah KV (2007) SV40 and human cancer: a review of recent data. Int J Cancer 120(2):215–223. https://doi.org/10.1002/ijc.22425 CrossRefPubMed

Lam WKJ, Chan JYK (2018) Recent advances in the management of nasopharyngeal carcinoma. F1000Res. https://doi.org/10.12688/f1000research.15066.1 CrossRefPubMedPubMedCentral

Zhao JJ, Zhou S, Chen CL, Zhang HX, Zhou ZQ, Wu ZR, Liu Y, Pan QZ, Zhu Q, Tang Y, Xia JC, Weng DS (2018) Clinical effect of adjuvant cytokine-induced killer cells immunotherapy in patients with stage II-IVB nasopharyngeal carcinoma after chemoradiotherapy: a propensity score analysis. J Cancer 9(22):4204–4214. https://doi.org/10.7150/jca.25790 CrossRefPubMedPubMedCentral

10.

Fernandes Q, Merhi M, Raza A, Inchakalody VP, Abdelouahab N, Zar Gul AR, Uddin S, Dermime S (2018) Role of Epstein–Barr virus in the pathogenesis of head and neck cancers and its potential as an immunotherapeutic target. Front Oncol 8:257. https://doi.org/10.3389/fonc.2018.00257 CrossRefPubMedPubMedCentral

11.

Rietbergen MM, Brakenhoff RH, Bloemena E, Witte BI, Snijders PJF, Heideman DAM, Boon D, Koljenovic S, Baatenburg-de Jong RJ, Leemans CR (2013) Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. Ann Oncol 24(11):2740–2745. https://doi.org/10.1093/annonc/mdt319 CrossRefPubMed

12.

Mirghani H, Amen F, Blanchard P, Moreau F, Guigay J, Hartl DM, Lacau St Guily J (2015) Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. Int J Cancer 136(7):1494–1503. https://doi.org/10.1002/ijc.28847 CrossRefPubMed

13.

Mirghani H, Blanchard P (2018) Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? Clin Transl Radiat Oncol 8:4–11. https://doi.org/10.1016/j.ctro.2017.10.005 CrossRefPubMed

14.

Carpen T, Sjoblom A, Lundberg M, Haglund C, Markkola A, Syrjanen S, Tarkkanen J, Makitie A, Hagstrom J, Mattila P (2018) Presenting symptoms and clinical findings in HPV-positive and HPV-negative oropharyngeal cancer patients. Acta Otolaryngol 138(5):513–518. https://doi.org/10.1080/00016489.2017.1405279 CrossRefPubMed

15.

Jouhi L, Halme E, Irjala H, Saarilahti K, Koivunen P, Pukkila M, Hagstrom J, Haglund C, Lindholm P, Hirvikoski P, Vaittinen S, Ellonen A, Tikanto J, Blomster H, Laranne J, Grenman R, Makitie A, Atula T (2018) Epidemiological and treatment-related factors contribute to improved outcome of oropharyngeal squamous cell carcinoma in Finland. Acta Oncol 57(4):541–551. https://doi.org/10.1080/0284186x.2017.1400688 CrossRefPubMed

16.

Habbous S, Chu KP, Qiu X, La Delfa A, Harland LT, Fadhel E, Hui A, Perez-Ordonez B, Weinreb I, Liu FF, Waldron J, O’Sullivan B, Goldstein D, Xu W, Huang SH, Liu G (2013) The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre. Cancer Epidemiol 37(6):820–829. https://doi.org/10.1016/j.canep.2013.09.011 CrossRefPubMed

17.

Stein AP, Saha S, Kraninger JL, Swick AD, Yu M, Lambert PF, Kimple RJ (2015) Prevalence of human papillomavirus in oropharyngeal cancer: a systematic review. Cancer J 21(3):138–146. https://doi.org/10.1097/PPO.0000000000000115 CrossRefPubMedPubMedCentral

18.

Carpen T, Saarilahti K, Haglund C, Markkola A, Tarkkanen J, Hagstrom J, Mattila P, Makitie A (2018) Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy. Strahlenther Onkol 194(8):759–770. https://doi.org/10.1007/s00066-018-1309-z CrossRefPubMed

19.

Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100(4):261–269. https://doi.org/10.1093/jnci/djn011 CrossRefPubMed

20.

Chang ET, Adami HO (2006) The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomark Prev 15(10):1765–1777. https://doi.org/10.1158/1055-9965.Epi-06-0353 CrossRef

21.

Svajdler M, Kaspirkova J, Mezencev R, Laco J, Torday T, Dubinsky P, Straka L, Ondic O, Michal M, Skalova A (2016) Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a non-endemic eastern european population. Neoplasma 63(01):107–114. https://doi.org/10.4149/neo_2016_013 CrossRefPubMed

22.

Stenmark MH, McHugh JB, Schipper M, Walline HM, Komarck C, Feng FY, Worden FP, Wolf GT, Chepeha DB, Prince ME, Bradford CR, Mukherji SK, Eisbruch A, Carey TE (2014) Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys 88(3):580–588. https://doi.org/10.1016/j.ijrobp.2013.11.246 CrossRefPubMedPubMedCentral

23.

Drop B, Strycharz-Dudziak M, Kliszczewska E, Polz-Dacewicz M (2017) Coinfection with Epstein-Barr virus (EBV), human papilloma virus (HPV) and polyoma BK virus (BKPyV) in laryngeal, oropharyngeal and oral cavity cancer. Int J Mol Sci. https://doi.org/10.3390/ijms18122752 CrossRefPubMedPubMedCentral

24.

Polz-Gruszka D, Morshed K, Jarzynski A, Polz-Dacewicz M (2015) Prevalence of polyoma BK Virus (BKPyV), Epstein–Barr virus (EBV) and human papilloma virus (HPV) in oropharyngeal cancer. Pol J Microbiol 64(4):323–328CrossRefPubMed

25.

Sastre-Garau X, Peter M, Avril M-F, Laude H, Couturier J, Rozenberg F, Almeida A, Boitier F, Carlotti A, Couturaud B, Dupin N (2009) Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis. J Pathol 218(1):48–56. https://doi.org/10.1002/path.2532 CrossRefPubMed

26.

Vazquez-Guillen JM, Palacios-Saucedo GC, Rivera-Morales LG, Alonzo-Morado MV, Burciaga-Bernal SB, Montufar-Martinez M, Ortiz-Lopez R, Gonzalez-Villasana V, Martinez-Torres AC, Serna-Hernandez JC, Hernandez-Martinez SJ, Castelan-Maldonado EE, Zavala-Pompa A, Montalvo-Banuelos MS, Garcia-Cabello R, Sanchez-Fresno EC, Rodriguez-Padilla C (2018) Infection and coinfection by human papillomavirus, Epstein–Barr virus and Merkel cell polyomavirus in patients with squamous cell carcinoma of the larynx: a retrospective study. PeerJ 6:e5834. https://doi.org/10.7717/peerj.5834 CrossRefPubMedPubMedCentral

27.

Martini F, Lazzarin L, Iaccheri L, Vignocchi B, Finocchiaro G, Magnani I, Serra M, Scotlandi K, Barbanti-Brodano G, Tognon M (2002) Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. Cancer 94(4):1037–1048CrossRefPubMed

28.

Cristaudo A, Foddis R, Vivaldi A, Buselli R, Gattini V, Guglielmi G, Cosentino F, Ottenga F, Ciancia E, Libener R, Filiberti R, Neri M, Betta P, Tognon M, Mutti L, Puntoni R (2005) SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Can Res 65(8):3049–3052. https://doi.org/10.1158/0008-5472.Can-04-2219 CrossRef

29.

Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (2017) AJCC Cancer Staging Manual, 8th edn. Springer, New York, p 2017CrossRef

30.

Lydiatt WM, Patel SG, O’Sullivan B, Brandwein, Ridge JA, Migliacci JC, Loomis AM, Shah JP (2017) Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 67(2):122–137. https://doi.org/10.3322/caac.21389 CrossRefPubMed

31.

Prigge E-S, Arbyn M, von Knebel Doeberitz M, Reuschenbach M (2017) Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis. Int J Cancer 140(5):1186–1198. https://doi.org/10.1002/ijc.30516 CrossRefPubMed

32.

Smeets SJ, Hesselink AT, Speel E-JM, Haesevoets A, Snijders PJF, Pawlita M, Meijer CJLM, Braakhuis BJM, Leemans CR, Brakenhoff RH (2007) A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 121(11):2465–2472. https://doi.org/10.1002/ijc.22980 CrossRefPubMed

33.

Romagosa C, Simonetti S, Lopez-Vicente L, Mazo A, Lleonart ME, Castellvi J, y Cajal SR (2011) p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 30(18):2087–2097. https://doi.org/10.1038/onc.2010.614 CrossRefPubMed

34.

Kuss-Duerkop SK, Westrich JA, Pyeon D (2018) DNA tumor virus regulation of host DNA methylation and its implications for immune evasion and oncogenesis. Viruses. https://doi.org/10.3390/v10020082 CrossRefPubMedPubMedCentral

35.

Carpen T, Sorsa T, Jouhi L, Tervahartiala T, Haglund C, Syrjanen S, Tarkkanen J, Mohamed H, Makitie A, Hagstrom J, Mattila PS (2019) High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the serum are associated with poor prognosis in HPV-negative squamous cell oropharyngeal cancer. Cancer Immunol Immunother 68(8):1263–1272. https://doi.org/10.1007/s00262-019-02362-4 CrossRefPubMedPubMedCentral

36.

Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefPubMedPubMedCentral

37.

Paaso AE, Louvanto K, Syrjanen KJ, Waterboer T, Grenman SE, Pawlita M, Syrjanen SM (2011) Lack of type-specific concordance between human papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa. J Gen Virol 92(Pt 9):2034–2046. https://doi.org/10.1099/vir.0.032011-0 CrossRefPubMed

38.

McNees AL, White ZS, Zanwar P, Vilchez RA, Butel JS (2005) Specific and quantitative detection of human polyomaviruses BKV, JCV, and SV40 by real time PCR. J Clin Virol 34(1):52–62. https://doi.org/10.1016/j.jcv.2004.12.018 CrossRefPubMed

39.

Jiang R, Ekshyyan O, Moore-Medlin T, Rong X, Nathan S, Gu X, Abreo F, Rosenthal EL, Shi M, Guidry JT, Scott RS, Hutt-Fletcher LM, Nathan C-AO (2015) Association between human papilloma virus/Epstein–Barr virus coinfection and oral carcinogenesis. J Oral Pathol Med 44(1):28–36. https://doi.org/10.1111/jop.12221 CrossRefPubMed

40.

Broccolo F, Ciccarese G, Rossi A, Anselmi L, Drago F, Toniolo A (2018) Human papillomavirus (HPV) and Epstein-Barr virus (EBV) in keratinizing versus non- keratinizing squamous cell carcinoma of the oropharynx. Infect Agents Cancer 13:32. https://doi.org/10.1186/s13027-018-0205-6 CrossRef

41.

Yin H, Qu J, Peng Q, Gan R (2019) Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis. Med Microbiol Immunol 208(5):573–583. https://doi.org/10.1007/s00430-018-0570-1 CrossRefPubMed

42.

Iwakiri D, Takada K (2010) Role of EBERs in the pathogenesis of EBV infection. Adv Cancer Res 107:119–136. https://doi.org/10.1016/s0065-230x(10)07004-1 CrossRefPubMed

43.

Kikuchi K, Noguchi Y, de Rivera MW, Hoshino M, Sakashita H, Yamada T, Inoue H, Miyazaki Y, Nozaki T, Gonzalez-Lopez BS, Ide F, Kusama K (2016) Detection of Epstein-Barr virus genome and latent infection gene expression in normal epithelia, epithelial dysplasia, and squamous cell carcinoma of the oral cavity. Tumour Biol 37(3):3389–3404. https://doi.org/10.1007/s13277-015-4167-7 CrossRefPubMed

44.

Cao Y (2017) EBV based cancer prevention and therapy in nasopharyngeal carcinoma. NPJ Precis Oncol 1(1):10. https://doi.org/10.1038/s41698-017-0018-x CrossRefPubMedPubMedCentral

45.

Chia W-K, Teo M, Wang W-W, Lee B, Ang S-F, Tai W-M, Chee C-L, Ng J, Kan R, Lim W-T, Tan S-H, Ong W-S, Cheung Y-B, Tan E-H, Connolly JE, Gottschalk S, Toh H-C (2014) Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther 22(1):132–139. https://doi.org/10.1038/mt.2013.242 CrossRefPubMed

46.

Guidry JT, Myers JE, Bienkowska-Haba M, Songock WK, Ma X, Shi M, Nathan CO, Bodily JM, Sapp MJ, Scott RS (2019) Inhibition of Epstein-Barr virus replication in human papillomavirus-immortalized keratinocytes. J Virol. https://doi.org/10.1128/jvi.01216-18 CrossRefPubMedPubMedCentral

47.

Zheng Y, Xia P, Zheng HC, Takahashi H, Masuda S, Takano Y (2010) The screening of viral risk factors in tongue and pharyngolaryngeal squamous carcinoma. Anticancer Res 30(4):1233–1238PubMed

48.

Kato A, Hulse KE, Tan BK, Schleimer RP (2013) B-lymphocyte lineage cells and the respiratory system. J Allergy Clin Immunol 131(4):933–957. https://doi.org/10.1016/j.jaci.2013.02.023 CrossRefPubMedPubMedCentral

49.

Chen ZW, Weinreb I, Kamel-Reid S, Perez-Ordonez B (2012) Equivocal p16 immunostaining in squamous cell carcinoma of the head and neck: staining patterns are suggestive of HPV status. Head Neck Pathol 6(4):422–429. https://doi.org/10.1007/s12105-012-0382-3 CrossRefPubMedPubMedCentral

50.

White MK, Khalili K (2006) Interaction of retinoblastoma protein family members with large T-antigen of primate polyomaviruses. Oncogene 25(38):5286–5293. https://doi.org/10.1038/sj.onc.1209618 CrossRefPubMed

51.

Al-Salam S, Awwad A, Alashari M (2014) Epstein-Barr virus infection is inversely correlated with the expression of retinoblastoma protein in Reed-Sternberg cells in classic Hodgkin lymphoma. Int J Clin Exp Pathol 7(11):7508–7517PubMedPubMedCentral

52.

Cannell EJ, Farrell PJ, Sinclair AJ (1996) Epstein–Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells. Oncogene 13(7):1413–1421PubMed

53.

Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100(6):407–420. https://doi.org/10.1093/jnci/djn025 CrossRefPubMed

54.

Dahlstrom KR, Bell D, Hanby D, Li G, Wang LE, Wei Q, Williams MD, Sturgis EM (2015) Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior. Oral Oncol 51(9):832–838. https://doi.org/10.1016/j.oraloncology.2015.06.005 CrossRefPubMedPubMedCentral

Title: Epstein–Barr virus (EBV) and polyomaviruses are detectable in oropharyngeal cancer and EBV may have prognostic impact
Authors: Timo Carpén
Stina Syrjänen
Lauri Jouhi
Reija Randen-Brady
Caj Haglund
Antti Mäkitie
Petri S. Mattila
Jaana Hagström
Publication date: 01-08-2020
Publisher: Springer Berlin Heidelberg
Keywords: Human Papillomavirus
Epstein-Barr Virus
Oropharyngeal Cancer
Published in: Cancer Immunology, Immunotherapy / Issue 8/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02570-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2020

Interleukin-33 pretreatment promotes metastatic growth of murine melanoma by reducing the cytotoxic capacity of CD8+ T cells and enhancing regulatory T cells

Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer

Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial

Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade

Characterising the prognostic potential of HLA-DR during colorectal cancer development

Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer